medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-2-79-85medsovet-45Research ArticleОнкологияOncologyПатогенетические особенности профилактики тромбогеморрагических осложнений у онкогинекологических больныхThe specifics of pathogenetic prevention of thrombotic and hemorrhagic complications in patients with gynecological cancersМакацарияА. Д.MakatsariyaA. D.noemail@neicon.ruВоробьевА. В.VorobyovA. V.noemail@neicon.ruПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияFirst Moscow State Medical University named after I.M. SechenovRussian Federation201630122016027985Copyright © Макацария А.Д., Воробьев А.В., 20162016Макацария А.Д., Воробьев А.В.Makatsariya A.D., Vorobyov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/45

В статье рассмотрены основные препараты антикоагулянтного действия, применяемые у онкологических больных, с учетом патогенеза гиперкоагуляционного статуса у таких больных: пероральные антикоагулянты, препараты гепарина, селективные ингибиторы Xa-фактора. Описаны основные преимущества препаратов низкомолекулярного гепарина по сравнению с нефракционированным гепарином. Даны рекомендации по профилактике тромботических осложнений у онкологических больных. Представлен обзор возможных осложнений гепаринотерапии и методы их профилактики.

The article tells about major anticoagulant medications used in cancer patients taking into account the pathogenesis of hypercoagulation status in these patients: oral anticoagulants, heparin medications, selective factor Xa-inhibitors. The main advantages of low molecular weight heparins versus unfractionated heparin are described. Recommendations for the prevention of thrombotic complications in cancer patients are provided. Possible complications of heparin therapy are reviewed, and the prevention methods are suggested.

низкомолекулярный гепаринпероральные антикоагулянтыгепарин-индуцированная тромбоцитопения профилактика тромбозовингибиторы Xa-фактораlow molecular weight heparinoral anticoagulantsheparin-induced thrombocytopeniathrombosis prophylaxisfactReferencesGray E, MuLLoy B, Barrowcliffe TW. Heparin and low-molecularweight heparin. Thromb Haemost, 2008, 99: 807-18.Gray E, MuLLoy B, Barrowcliffe TW. Heparin and low-molecularweight heparin. Thromb Haemost, 2008, 99: 807-18.Макацария А.Д., Воробьев А.В., Бицадзе В.О. Злокачественные новообразования, тромбофилия, тромбозы. Монография. Триада-Х, М., РФ, 2008, 650 стр.Макацария А.Д., Воробьев А.В., Бицадзе В.О. Злокачественные новообразования, тромбофилия, тромбозы. Монография. Триада-Х, М., РФ, 2008, 650 стр.Donati MB, Falanga A. Patogenetic Mechanisms of Thrombosis in Malignancy. Acta Haematol, 2001, 106: 18-24.Donati MB, Falanga A. Patogenetic Mechanisms of Thrombosis in Malignancy. Acta Haematol, 2001, 106: 18-24.van Dongen CJ, Mac Gillavry MR, Prins MH. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst. Rev, 2005, Issue 3. Art. № CD003074.van Dongen CJ, Mac Gillavry MR, Prins MH. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst. Rev, 2005, Issue 3. Art. № CD003074.Falanga A, Marchetti M, Vignoli A. Pathogenesis of thrombosis in cancer. Thromb and cancer, 2004, 30: 11-23.Falanga A, Marchetti M, Vignoli A. Pathogenesis of thrombosis in cancer. Thromb and cancer, 2004, 30: 11-23.Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene, 2003, 22: 6524-36.Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene, 2003, 22: 6524-36.Lee AYY. Screening for occult cancer in patients with idiopathic venous thromboembolism. No. J Thromb Haemost, 2003. 1: 2273-2274.Lee AYY. Screening for occult cancer in patients with idiopathic venous thromboembolism. No. J Thromb Haemost, 2003. 1: 2273-2274.Воробьев А.В. Злокачественные заболевания и тромбозы. Вопросы акушерства, гинекологии и перинатологии, 2008, 2, 7: 18-25.Воробьев А.В. Злокачественные заболевания и тромбозы. Вопросы акушерства, гинекологии и перинатологии, 2008, 2, 7: 18-25.Цыб А.Ф., Сушкевич ПН., Балуда М.В., Воробьев А.В., Чабров А.М. Принципы профилактики тромботических осложнений у онкологических больных (солидные образования). Пособие для врачей. Обнинск, РФ, 2008, 42 стр.Цыб А.Ф., Сушкевич ПН., Балуда М.В., Воробьев А.В., Чабров А.М. Принципы профилактики тромботических осложнений у онкологических больных (солидные образования). Пособие для врачей. Обнинск, РФ, 2008, 42 стр.Gray E, Rigsby P, Behr-Gross ME. Collaborative study to establish the low-molecular-mass heparin for assay - European Pharmacopoeia Biological Reference Preparation. Pharmeuropa Bio, 2004. 1: 59-76.Gray E, Rigsby P, Behr-Gross ME. Collaborative study to establish the low-molecular-mass heparin for assay - European Pharmacopoeia Biological Reference Preparation. Pharmeuropa Bio, 2004. 1: 59-76.Макацария А.Д. и соавт. Тромбогеморрагические осложнения в акушерско-гинекологической практике. Руководство для врачей под ред. АД. Макацария. М.: МИА, 2011.Макацария А.Д. и соавт. Тромбогеморрагические осложнения в акушерско-гинекологической практике. Руководство для врачей под ред. АД. Макацария. М.: МИА, 2011.Шилова А.Н., Лазарев А.Ф., Воробьев ПА., Баркаган З.С., Ходоренко СА., Котовщикова Е.Ф., Момот А.П., Буевич Е.И. Контролируемая антитромботическая профилактика онкотромбозов: клинико-экономический анализ. Сибирский онкологический журнал, 2008, 3: 74-76.Шилова А.Н., Лазарев А.Ф., Воробьев ПА., Баркаган З.С., Ходоренко СА., Котовщикова Е.Ф., Момот А.П., Буевич Е.И. Контролируемая антитромботическая профилактика онкотромбозов: клинико-экономический анализ. Сибирский онкологический журнал, 2008, 3: 74-76.Zacharski Leo R. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Seminars in thrombosis and hemostasis, 2003, 29: 239-46.Zacharski Leo R. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Seminars in thrombosis and hemostasis, 2003, 29: 239-46.Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood, 2002, 100, 10: 3484-3488.Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood, 2002, 100, 10: 3484-3488.Samama MM, Gerotziafas G. Comparative Pharmacokinetics of LMWHs. Semin Thromb Hemost, 2000, 26: 31-6.Samama MM, Gerotziafas G. Comparative Pharmacokinetics of LMWHs. Semin Thromb Hemost, 2000, 26: 31-6.Guerrini M, Guglieri S, Naggi A, Sasisekharan R, Torri G. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost, 2007, 33: 478-87.Guerrini M, Guglieri S, Naggi A, Sasisekharan R, Torri G. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost, 2007, 33: 478-87.Agnes YY Lee, Mark N Levine, Ross I Baker, Chris Bowden, Ajay K Kakkar, Martin Prins, Frederick R Rickles, Jim A. Julian, M Math, Susan Haley, Michael J Kovacs, and Michael Gent. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med, 2003, 349: 146-153.Agnes YY Lee, Mark N Levine, Ross I Baker, Chris Bowden, Ajay K Kakkar, Martin Prins, Frederick R Rickles, Jim A. Julian, M Math, Susan Haley, Michael J Kovacs, and Michael Gent. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med, 2003, 349: 146-153.Klerk CPW, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol., 2005, 23, 10: 2130-2135.Klerk CPW, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol., 2005, 23, 10: 2130-2135.Meyer G, Marjanovic Z, Valcke J et al. Comparison of low molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer a randomized controlled study. Arch. Intern. Med., 2002, 162, 15: 1729-1735.Meyer G, Marjanovic Z, Valcke J et al. Comparison of low molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer a randomized controlled study. Arch. Intern. Med., 2002, 162, 15: 1729-1735.EMEA. Guidelines on Clinical and Non-Clinical Development of Medicinal Products Containing Low-Molecular-Weight Heparins. London: European Medical Agency; 2009. EMEA/CHMP/ BMWP/11826407enfin.pdf. Accessed July 29, 2010.EMEA. Guidelines on Clinical and Non-Clinical Development of Medicinal Products Containing Low-Molecular-Weight Heparins. London: European Medical Agency; 2009. EMEA/CHMP/ BMWP/11826407enfin.pdf. Accessed July 29, 2010.Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest, 2001, 119: Suppl. 1: 64S-94S.Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest, 2001, 119: Suppl. 1: 64S-94S.Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Ассоциация флебологов России, Всероссийское общество хирургов. М.: Медиа Сфера, 2010.Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Ассоциация флебологов России, Всероссийское общество хирургов. М.: Медиа Сфера, 2010.Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med, 2000, 160: 3415-20.Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med, 2000, 160: 3415-20.Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol, 2005 Jun, 6(6): 401-10.Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol, 2005 Jun, 6(6): 401-10.Prandoni P, Lensing AW, Buller HR et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N. Engl. J. Med., 1992, 327, 16: 1128-1133.Prandoni P, Lensing AW, Buller HR et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N. Engl. J. Med., 1992, 327, 16: 1128-1133.Makatsaria A.D., Vorobyov A.V., Bitsadze V.O. Malignancies, thrombophilia, thrombosis. Monograph. Triada-Kh, Moscow, RF, 2008, 650 p.Makatsaria A.D., Vorobyov A.V., Bitsadze V.O. Malignancies, thrombophilia, thrombosis. Monograph. Triada-Kh, Moscow, RF, 2008, 650 p.Vorobyov A.V. Malignant diseases and thrombosis. Issues of Obstetrics, Gynecology and Perinatology, 2008, 2 (7): 18-25.Vorobyov A.V. Malignant diseases and thrombosis. Issues of Obstetrics, Gynecology and Perinatology, 2008, 2 (7): 18-25.Tsyb A.F., Sushkevich G.N., Baluda M.V., Vorobyov A.V., Chabrov A.M. Principles of prevention of thrombotic complications in patients with cancer (solid tumors). Doctor's Manual. Obninsk, RF, 2008, 42 p.Tsyb A.F., Sushkevich G.N., Baluda M.V., Vorobyov A.V., Chabrov A.M. Principles of prevention of thrombotic complications in patients with cancer (solid tumors). Doctor's Manual. Obninsk, RF, 2008, 42 p.Makatsaria A.D. et al. Trombotic and hemorrhagic complications in obstetric and gynecological practice. A guide for physicians ed. by A.D. Makatsaria. М.: MIA, 2011.Makatsaria A.D. et al. Trombotic and hemorrhagic complications in obstetric and gynecological practice. A guide for physicians ed. by A.D. Makatsaria. М.: MIA, 2011.Shilova A.N., Lazarev A.., Vorobyov P.A., Barkagan Z.S., Khodorenko S.A., Kotovschikova E.F., Momot A.P., Buevich E.I. Controlled antithrombotic prophylaxis of onco-thrombosis: clinical and economic analysis. Sibirskiy Onkologicheskiy Zhurnal, 2008, 3: 74-76.Shilova A.N., Lazarev A.., Vorobyov P.A., Barkagan Z.S., Khodorenko S.A., Kotovschikova E.F., Momot A.P., Buevich E.I. Controlled antithrombotic prophylaxis of onco-thrombosis: clinical and economic analysis. Sibirskiy Onkologicheskiy Zhurnal, 2008, 3: 74-76.Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic events. Association of Phlebology Russia, Russian Society of Surgeons. M .: Media Sphere 2010.Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic events. Association of Phlebology Russia, Russian Society of Surgeons. M .: Media Sphere 2010.

The authors declare that there are no conflicts of interest present.